Form D · Biotechnology
NGX Bio, Inc.
San Francisco, CA · CIK 0001635908
Offering snapshot reported Sep 2, 2015 · SEC filing
- Reported sold
- $300K Offering amount: $600K
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 20, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 2, 2015 | Initial | $300,000 | No comparison | 7 | SEC filing |
| Mar 10, 2015 | Initial | $375,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-246876
Source: Form D, filed Sep 2, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alexi Andreev | Director |
| Amit Kumar | Director |
| Dmitri Petrov | Director |
| Sam Tolkoff | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
739 Bryant Street
San Francisco, CA, 92107
San Francisco, CA, 92107